Human IL-12p70 ELISA
- Regulatory Status
- RUO
- Incubation time
- 1 x 3 hr,1 x 30 min,1 x 15 min
- Kit size
- 12 x 8
- Specimen / Volumes
- 100 μL supernatants, buffered solutions, serum, plasma
- Standard range
- 6.25 - 200 pg/mL
- Substrate / isotope
- TMB 450 nm
Intended use
The Human IL-12p70 ELISA kit is a solid phase sandwich ELISA for the in-vitro qualitative and quantitative determination of IL-12p70 in supernatants, buffered solutions or serum and plasma samples. This assay will recognise both natural and recombinant human IL-12p70.
Summary
L-12 is a pleiotropic cytokine formely called cytotoxic lymphocyte maturation factor (CLMF) or natural killer cell stimulatory factor (NKSF). IL-12 is a potent regulator of cell mediated immune response produced by activated monocytes/macrophages cells, dendritics cells, neutrophils, B lymphocytes and connective tissue type mast cells. IL-12 is produced in response to bacterial products, intracellular pathogens, or upon interaction with activated T cells. The biologically active form of IL-12 is a 70 kDa heterodimeric glycoprotein consisting of disulfide-linked 35 kDa (designated p35) light chain and 40 kDa (p40) heavy chain subunits. The p35 subunit has homology to IL-6, while p40 has homology with IL-23. The two subunits are genetically unrelated and are regulated independently: IL-12p40 is produced constitutively and in excess of p35. The receptor for IL-12p70 is composed of two subunits, IL-12R beta 1 and IL-12R beta 2 which bind p40 and p35 subunits respectively. Through JAKS and STAT4 signaling pathway, IL-12 induces IFNγ productionand increases proliferation and cytotoxic activity of T and NK cells. Moreover, IL-12 induces CD4+ polarization to the Th1 phenotype that mediates immunity against intracellular pathogens. Aberrant level of IL-12 in plasma was described in several immune diseases: multiple sclerosis, autoimmune encephalitis, autoimmune subcutaneous lupus erythramatosus and rheumatoid arthritis. High level have also been reported for chronic inflammatory reactions, bacterial and viral infection (mycobacterial, salmonella, HIV). Following these properties and its role in autoimmunity, IL-12 was described as a target in the treatment of autoimmune and systemic inflammatory diseases (Crohn’s disease, Psoriasis, multiple sclerosis).
This kit has been configured for research use only. Not suitable for use in therapeutic procedures.
- Dorman SE and al, Cytokine Growth Factor Rev. 2000 Dec;11(4):321-33.
- Hsieh CS and al, Science. 1993 Apr 23;260(5107):547-9.
- Kang BY and al, Cell Signal. 2005 Jun;17(6):665-73.
- Sun L and al, Cytokine. 2015 Oct;75(2):249-55.
- Temblay JN and al, J Allergy Clin Immunol. 2007 Sep;120(3):659-65.
- Wang KS and al, Blood. 2000 May 15;95(10):3183-90.
- Watford WT and al, Cytokine Growth Factor Rev. 2003 Oct;14(5):361-8.
- Zhang S and al, Biochem Biophys Res Commun. 2008 Aug 8;372(4):509-12.
- Zundler S and al, Cytokine Growth Factor Rev. 2015 Oct;26(5):559-68.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.